ArticleScientific reports2025
CD206 and dust particles are prognostic biomarkers of progressive fibrosing interstitial lung disease associated with air pollutant exposure.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Geospatial and temporal trends of interstitial lung disease subtypes and KL-6 biomarker in China: a nationwide study (2016-2024).Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current management strategies for progressive fibrosing interstitial lung disease (PF-ILD) and non-PF-ILD differ significantly, underscoring the need for early identification of PF-ILD patients. We analyzed the expression of macrophage markers and the number of dust particles (DP) in lung tissue, as well as complete blood count and blood chemistry tests to identify biomarkers of PF-ILD, and examined the effect of certain pollutants on these biomarkers. Lung biopsies were collected from 73 non-PF-ILD patients and 36 PF-ILD patients. DP were quantified in alveolar wall cells (DP-aw) and desquamated epithelial cells (DP-desq) using polarizing light microscopy. Expression of CD206, transforming growth factor β1 (TGF-β1), connective tissue growth factor (CTGF), C-X-C motif ligand 13 (CXCL13), fibroblast growth factor 2 (FGF-2), tumor necrosis factor α (TNFα), and interleukin 1β (IL-1β) was assessed in lung tissue by immunohistochemistry. The numbers of DP-desq, pulmonary expression of CXCL13, IL-1β and CD206 were higher in ILD patients resided for ≥ 15 days per year in places with 24-hour ambient PM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.